GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (NAS:VIVO) » Definitions » ROC %

Meridian Bioscience (Meridian Bioscience) ROC % : 13.12% (As of Sep. 2022)


View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Meridian Bioscience's annualized return on capital (ROC %) for the quarter that ended in Sep. 2022 was 13.12%.

As of today (2024-06-06), Meridian Bioscience's WACC % is 0.00%. Meridian Bioscience's ROC % is 0.00% (calculated using TTM income statement data). Meridian Bioscience earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Meridian Bioscience ROC % Historical Data

The historical data trend for Meridian Bioscience's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience ROC % Chart

Meridian Bioscience Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.43 13.36 16.54 21.63 16.58

Meridian Bioscience Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.35 17.41 31.99 11.62 13.12

Meridian Bioscience ROC % Calculation

Meridian Bioscience's annualized Return on Capital (ROC %) for the fiscal year that ended in Sep. 2022 is calculated as:

ROC % (A: Sep. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Sep. 2021 ) + Invested Capital (A: Sep. 2022 ))/ count )
=75.95 * ( 1 - 21.83% )/( (372.275 + 343.872)/ 2 )
=59.370115/358.0735
=16.58 %

where

Meridian Bioscience's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2022 is calculated as:

ROC % (Q: Sep. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2022 ) + Invested Capital (Q: Sep. 2022 ))/ count )
=37.244 * ( 1 - -23.14% )/( (355.016 + 343.872)/ 2 )
=45.8622616/349.444
=13.12 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Meridian Bioscience  (NAS:VIVO) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Meridian Bioscience's WACC % is 0.00%. Meridian Bioscience's ROC % is 0.00% (calculated using TTM income statement data). Meridian Bioscience earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Meridian Bioscience ROC % Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Meridian Bioscience (Meridian Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
3471 River Hills Drive, Cincinnati, OH, USA, 45244
Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.
Executives
Julie Diana Smith officer: Sr VP, Controller, PAO 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John P. Kenny director, officer: Chief Executive Officer 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Andrew S. Kitzmiller officer: EVP & CFO ONE BATESVILLE BLVD., BATESVILLE IN 47006
Bryan T Baldasare officer: Interim CFO & Chief Acctg Off 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Rice John Mccune Jr. director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Bihl Anthony P Iii director 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Tony Serafini-lamanna officer: Executive VP-Diagnostics 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Felicia Williams director C/O MACY'S, INC., 151 WEST 34TH STREET, NEW YORK NY 10001
John Mcilwraith director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
David Phillips director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
James M. Anderson director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Dwight E Ellingwood director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lawrence Baldini officer: Exec VP, Operations & IS 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric S. Rasmussen officer: EVP, Bus. Development/Strategy 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lourdes Weltzien officer: EVP, Life Science 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244

Meridian Bioscience (Meridian Bioscience) Headlines